Advanced Search

Recombinant Dna Stocks List

Symbol Grade Name % Change
PLX B Protalix BioTherapeutics, Inc. 3.85
AZRX F AzurRx BioPharma, Inc. -2.52
INZY F Inozyme Pharma, Inc. -7.23
View As Page of Charts
Related Industries: Biotechnology
Related Stock Lists: Biology Biopharmaceutical Biotechnology Life Sciences Molecular Biology Acetylcholine Autoimmune Disorders Biodefense Choline Cholinesterase Disease Enzyme Replacement Therapy Exocrine Pancreatic Insufficiency Fabry Disease Fusion Protein Gastrointestinal Gastrointestinal Disease Gastrointestinal Diseases Gaucher Disease Genetic Disease

Related ETFs - A few ETFs which own one or more of the above listed Recombinant Dna stocks.

Symbol Grade Name Weight
PQSG B PGIM QMA Strategic Alpha Small-Cap Growth ETF 0.14
IBBJ F Defiance Nasdaq Junior Biotechnology ETF 0.13
IWC D iShares Microcap ETF 0.05
IBB D iShares Nasdaq Biotechnology Index Fund 0.04
BIB D ProShares Ultra Nasdaq Biotechnology 0.03
View all Recombinant Dna related ETFs...
Compare ETFs
  • Compare IWC to IBB
  • Compare PQSG to IBBJ
  • Compare PQSG to IWC

    • Recent Signals

    Date Stock Signal Type
    2021-04-16 AZRX Narrow Range Bar Range Contraction
    2021-04-16 AZRX Lizard Bullish Bullish Day Trade Setup
    2021-04-16 AZRX Hammer Candlestick Bullish
    2021-04-16 INZY Expansion Pivot Sell Setup Bearish Swing Setup
    2021-04-16 INZY 50 DMA Resistance Bearish
    2021-04-16 INZY MACD Bearish Signal Line Cross Bearish
    2021-04-16 INZY Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
    2021-04-16 INZY Fell Below 20 DMA Bearish
    2021-04-16 PLX Pocket Pivot Bullish Swing Setup
    2021-04-16 PLX Expansion Breakout Bullish Swing Setup
    2021-04-16 PLX Upper Bollinger Band Walk Strength

    Recent News for Recombinant Dna Stocks

    Date Stock Title
    Apr 14 INZY Inozyme Pharma reports data from burden of illness study in fatal genetic diseases
    Apr 14 INZY Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
    Apr 13 AZRX AzurRx Biopharma engages PPD to manage niclosamide clinical trial
    Apr 13 AZRX AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
    Related Industries: Biotechnology
    Related Stock Lists: Biology Biopharmaceutical Biotechnology Life Sciences Molecular Biology Acetylcholine Autoimmune Disorders Biodefense Choline Cholinesterase Disease Enzyme Replacement Therapy Exocrine Pancreatic Insufficiency Fabry Disease Fusion Protein Gastrointestinal Gastrointestinal Disease Gastrointestinal Diseases Gaucher Disease Genetic Disease

    Browse All Tags